Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Formosa Laboratories, Inc. (4746.TW)
Taoyuan City, TPE, TW
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.54% | -3.30% | +0.00% | -8.98% | -19.66% | -11.13% | -22.04% | -39.49% | -23.62% | -41.14% | -42.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+2.5% Q1'26: -7.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+182.3% ★ Q1'26: -84.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+19.0% Q1'26: -8.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+16.6% ★ Q1'26: +14.2% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+6.5% ★ Q1'26: +3.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-10.3% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.67× Q1'26: 3.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.60B
est: 2.58B (+0.7%)
|
3.19B
est: 3.15B (+1.4%)
|
2.54B
est: 2.54B (+0.1%)
|
2.69B
est: 2.76B (-2.6%)
|
2.76B
est: 2.71B (+1.8%)
|
3.08B
est: 2.85B (+7.9%)
|
3.14B
est: 3.29B (-4.3%)
|
3.77B
est: 3.77B (-0.2%)
|
4.36B
est: 4.69B (-7.0%)
|
4.73B
est: 4.60B (+2.8%)
|
4.85B
est: 5.02B (-3.4%)
|
4.86B
4.86B – 4.86B
-3.3% YoY
|
| EBITDA |
556.70M
est: 736.37M (-24.4%)
|
928.52M
est: 898.23M (+3.4%)
|
616.22M
est: 724.25M (-14.9%)
|
481.65M
est: 787.99M (-38.9%)
|
372.91M
est: 773.99M (-51.8%)
|
870.23M
est: 813.98M (+6.9%)
|
1.58B
est: 938.22M (+68.1%)
|
823.42M
est: 1.08B (-23.6%)
|
1.16B
est: 1.34B (-12.9%)
|
746.86M
est: 1.31B (-43.0%)
|
1.35B
est: 1.43B (-5.4%)
|
1.38B
1.38B – 1.38B
-3.3% YoY
|
| EBIT |
376.86M
est: 406.19M (-7.2%)
|
644.43M
est: 495.47M (+30.1%)
|
378.20M
est: 399.50M (-5.3%)
|
163.95M
est: 434.66M (-62.3%)
|
-8.90M
est: 426.94M (-102.1%)
|
389.41M
est: 448.99M (-13.3%)
|
1.12B
est: 517.52M (+115.6%)
|
352.50M
est: 594.40M (-40.7%)
|
171.56M
est: 765.49M (-77.6%)
|
237.77M
est: 751.10M (-68.3%)
|
803.18M
est: 819.32M (-2.0%)
|
792.48M
792.48M – 792.48M
-3.3% YoY
|
| Net Income |
282.39M
est: 385.89M (-26.8%)
|
483.44M
est: 665.49M (-27.4%)
|
238.65M
est: 341.67M (-30.2%)
|
176.82M
est: 142.00M (+24.5%)
|
-41.06M
est: 136.04M (-130.2%)
|
400.03M
est: 649.38M (-38.4%)
|
1.25B
est: 91.39M (+1,266.7%)
|
216.81M
est: 1.67B (-87.0%)
|
126.24M
est: 229.66M (-45.0%)
|
157.27M
est: 421.93M (-62.7%)
|
441.11M
est: 679.83M (-35.1%)
|
208.27M
208.27M – 208.27M
-69.4% YoY
|
| SGA |
271.44M
est: 294.71M (-7.9%)
|
322.20M
est: 359.49M (-10.4%)
|
333.08M
est: 289.86M (+14.9%)
|
397.91M
est: 315.37M (+26.2%)
|
345.16M
est: 309.77M (+11.4%)
|
338.25M
est: 325.77M (+3.8%)
|
453.14M
est: 375.49M (+20.7%)
|
421.34M
est: 431.27M (-2.3%)
|
432.95M
est: 531.57M (-18.6%)
|
502.26M
est: 521.58M (-3.7%)
|
510.08M
est: 568.95M (-10.3%)
|
550.31M
550.31M – 550.31M
-3.3% YoY
|
| EPS |
3.31
est: 3.21 (+3.2%)
|
5.48
est: 5.53 (-1.0%)
|
2.62
est: 2.84 (-7.8%)
|
1.78
est: 1.18 (+50.7%)
|
-0.41
est: 1.13 (-136.2%)
|
3.78
est: 5.40 (-30.0%)
|
10.92
est: 0.76 (+1,336.8%)
|
1.80
est: 13.87 (-87.0%)
|
1.05
est: 2.13 (-50.7%)
|
1.31
est: 3.91 (-66.5%)
|
3.67
est: 6.30 (-41.7%)
|
1.93
1.93 – 1.93
-69.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 20.6K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 118.2K | 0.65% |
| 3 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 19.9K | 0.35% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 13.8K | 0.56% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 366.9K | 0.39% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 67.2K | 0.46% |
| 7 | Avantis Emerging Markets Value ETF AVES | 0.00% | 37.8K | 0.36% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 10.3K | 0.33% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 172.0K | 0.29% |
| 10 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 3.4K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen-Yu Cheng | Chairman, President & Manager | 10M | — |
| Chien-Fei Lin | Chief Information Security Officer | — | — |
| Hank Chen | Senior Vice President of Production | — | male |
| Hengui Huang | Senior Vice President of Quality & Regulatory Compliance Division | — | male |
| Ling-Fang Yang | Vice President | — | — |
| Shan-Jan Liou | Senior Vice President of Business | — | female |
| Xian-Gui Huang | Vice President | — | — |
| Yu Zhen Luo | Head of Accounting & Accounting Supervisor | — | — |
| Chai-Sung Chen | Senior Vice President of PD | — | male |
| Yu-Chen Lo | Senior Vice President of Corporate Support Division | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4746.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
